News | December 25, 2025
Tanabe Pharma America transfers RADICAVA business to Shionogi
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
NUFYMCO BLA has been approved by the USFDA
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The company also reported significant progress toward its internally defined Sustainable Development Goals
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The initiative is focused on a problem that continues to plague cancer outcomes in India
Subscribe To Our Newsletter & Stay Updated
